<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168908</url>
  </required_header>
  <id_info>
    <org_study_id>NA-00036602</org_study_id>
    <nct_id>NCT01168908</nct_id>
  </id_info>
  <brief_title>Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy</brief_title>
  <acronym>REVERSE-DBMD</acronym>
  <official_title>Phase 2 Clinical Trial of Sildenafil for Cardiac Dysfunction in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study, supported by Charley's Fund, Inc., is being done to determine if the drug
      RevatioÂ®(also known as Sildenafil), as compared to placebo (an inactive substance that looks
      like the study drug, but contains no medication), improves heart function in people with
      Duchenne Muscular Dystrophy and Becker Muscular Dystrophy (DBMD).

      In people with DBMD, dystrophin is not present or lacking in heart and muscle. This is
      associated with abnormalities in an enzyme called &quot;neuronal nitric oxide synthase&quot; or nNOS,
      and leads to decreases in &quot;cyclic GMP,&quot; which is necessary for proper function of those
      muscles. Revatio blocks an enzyme called phosphodiesterase 5 (PDE5), and helps to restore the
      normal amounts of cyclic GMP. The purpose of this research is to determine if Revatio is safe
      for people with DBMD and if it can improve heart function.

      Hypothesis : PDE5 inhibition, with the use of Revatio, will improve cardiac function in
      patients with DBMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is focused on cardiovascular disease due to dystrophin deficiency.
      Dystrophin is normally localized to the muscle cell membrane where it interacts with a
      complex of proteins including neuronal nitric oxide synthase (nNOS). DMD gene mutations lead
      to the loss of dystrophin and to mislocalization and reduced activity of nNOS, consequently
      reducing cyclic guanosine monophosphate (cGMP) and the activity of its downstream effector,
      protein kinase G. Our group and others have shown that inhibition of phosphodiesterase 5
      (PDE5) leads to favorable cardiac remodeling and improved vascular tone in animal models of
      heart failure.

      This will be a phase 2, randomized, double-blind, placebo-controlled single center study for
      6 months followed by open-label period of 6 months in which all enrolled subjects receive
      Revatio (a PDE5 inhibitor). A single dose of Revatio (20 mg three times daily) will be tested
      based on the safety and efficacy of that dose for treatment of pulmonary hypertension.

      The primary endpoint will be the change in cardiac left ventricular end-systolic volume
      (LVESV) as determined by cardiac MRI after 6 months of Revatio compared to baseline. A 10%
      change in LVESV will be considered significant. This degree of improvement has generally been
      observed in cardiac therapies that improve survival such as ACE inhibitors, beta blockers,
      and cardiac resynchronization. The change from baseline in LVESV after 6 months of Revatio
      will be compared to the change in LVESV over 6 months with placebo. The study will extend for
      an additional 6 months of open-label Revatio to provide data on 6 months versus 12 months of
      Revatio treatment. Additional secondary endpoints will include differences in systolic and
      diastolic LV function by MRI, differences in LV mass and fibrosis by MRI, brachial
      flow-mediated vasodilation (peripheral endothelial function), and targeted exploratory
      assessment of differences in skeletal muscle function using forced vital capacity (FVC) and
      pincher and grip testing. Safety will be assessed by differences in the frequency and grade
      of adverse events

      The study is taking place at the Kennedy Krieger Institute/Johns Hopkins Medical Institutions
      in Baltimore, MD. The trial requires out-patient visits over a 12-month period. Travel funds,
      through a grant from Ryan's Quest, are available.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    As recommended by the DSMB.
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cardiac Left Ventricular End-systolic Volume (LVESV) by Cardiac Magnetic Resonance (CMR) Imaging.</measure>
    <time_frame>6 months compared to baseline</time_frame>
    <description>To determine whether a 6 month trial of oral sildenafil compared to placebo improves cardiac contractile function in DBMD as determined by a &gt; 10% decline in end-systolic volume as detected by CMR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Systolic and Diastolic Function by CMR</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Cardiac volumes and systolic ejection parameters will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Mass</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Left ventricular (LV) mass will be measured by CMR .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC) by Pulmonary Function Testing</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Skeletal muscle function of the diaphragm will be measured using FVC by pulmonary function testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Skeletal Muscle Strength</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Skeletal muscle strength will be assessed by pincher and grip dynamometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection Fraction</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Becker Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Revatio (sildenafil)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>20mg tablet three times daily</description>
    <arm_group_label>Revatio (sildenafil)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DBMD as determined by either a skeletal muscle biopsy demonstrating absence or lack of
             dystrophin, and/or genetic testing showing a mutation in the dystrophin gene
             predictive of DBMD, as well as a consistent physical examination

          2. Male gender

          3. Age greater than or equal to 18 years

          4. Cardiac dysfunction with ejection fraction less than or equal to 50% as determined by
             echocardiogram, cardiac MRI, or multi-gated acquisition (MUGA) scan

          5. On a stable dose of ACE-inhibitor or angiotensin receptor blocker (ARB) for at least 3
             months; beta-adrenergic receptor blockers and glucocorticosteroids are not required
             but if used, a stable dose for at least 3 months is required.

          6. Ability of the subject or legal guardian to provide informed consent

          7. Ability to adhere with study follow-up

          8. Willingness to abstain from food and alcohol for 8 hours prior to FMD

        Exclusion Criteria:

          1. Use of nitrates or alpha-adrenergic receptor blockers

          2. Known intolerance or allergy to sildenafil, or a history of any severe allergic or
             anaphylactic reactions

          3. Any medical or psychosocial condition, which, in the view of the study investigator,
             makes study participation inadvisable

          4. Known hereditary retinal disorder such as retinitis pigmentosa

          5. History of priapism or conditions that may predispose to priapism such as sickle cell
             anemia, multiple myeloma, or leukemia

          6. Bleeding disorders

          7. Active tobacco use

          8. Chronic atrial fibrillation or frequent arrhythmia that would result in an irregular
             pulse

          9. Factors that would preclude obtaining an MRI study - (e.g. implantable pacemaker or
             cardioverter-defibrillator; body habitus cannot fit into scanner)

         10. Systolic blood pressure (SBP) less than 85 mmHg at baseline evaluation

         11. Chronic kidney disease stages 4 and 5: GFR&lt; 30 mL/min/1.73 m2 as determined by serum
             cystatin C level and the equation eGFRcys = 76.7 x (serum cystatin C-1.18)

         12. Current use of sildenafil.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel P Judge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn R. Wagner, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Kennedy Krieger Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kennedy Krieger Institute, Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2010</study_first_posted>
  <results_first_submitted>August 24, 2017</results_first_submitted>
  <results_first_submitted_qc>March 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2018</results_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</investigator_affiliation>
    <investigator_full_name>Kathryn Wagner</investigator_full_name>
    <investigator_title>Associate Professor of Neurology, Johns Hopkins University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Clinical trial</keyword>
  <keyword>Revatio</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <keyword>Duchenne</keyword>
  <keyword>Becker</keyword>
  <keyword>Adult</keyword>
  <keyword>Adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Revatio (Sildenafil)</title>
          <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind, Placebo Controlled</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Revatio (Sildenafil)</title>
          <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="8.2"/>
                    <measurement group_id="B2" value="22.6" spread="4.4"/>
                    <measurement group_id="B3" value="24.05" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiac Left Ventricular End-systolic Volume (LVESV) by Cardiac Magnetic Resonance (CMR) Imaging.</title>
        <description>To determine whether a 6 month trial of oral sildenafil compared to placebo improves cardiac contractile function in DBMD as determined by a &gt; 10% decline in end-systolic volume as detected by CMR.</description>
        <time_frame>6 months compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revatio (Sildenafil)</title>
            <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Left Ventricular End-systolic Volume (LVESV) by Cardiac Magnetic Resonance (CMR) Imaging.</title>
          <description>To determine whether a 6 month trial of oral sildenafil compared to placebo improves cardiac contractile function in DBMD as determined by a &gt; 10% decline in end-systolic volume as detected by CMR.</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="23.61"/>
                    <measurement group_id="O2" value="-0.19" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cardiac Systolic and Diastolic Function by CMR</title>
        <description>Cardiac volumes and systolic ejection parameters will be measured.</description>
        <time_frame>6 months and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revatio (Sildenafil)</title>
            <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Systolic and Diastolic Function by CMR</title>
          <description>Cardiac volumes and systolic ejection parameters will be measured.</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV end-diastolic volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.54" spread="18.85"/>
                    <measurement group_id="O2" value="0.24" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stroke volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="9.75"/>
                    <measurement group_id="O2" value="0.43" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cardiac Mass</title>
        <description>Left ventricular (LV) mass will be measured by CMR .</description>
        <time_frame>6 months and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revatio (Sildenafil)</title>
            <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Mass</title>
          <description>Left ventricular (LV) mass will be measured by CMR .</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="7.03"/>
                    <measurement group_id="O2" value="-1.05" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Vital Capacity (FVC) by Pulmonary Function Testing</title>
        <description>Skeletal muscle function of the diaphragm will be measured using FVC by pulmonary function testing.</description>
        <time_frame>6 months and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revatio (Sildenafil)</title>
            <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Vital Capacity (FVC) by Pulmonary Function Testing</title>
          <description>Skeletal muscle function of the diaphragm will be measured using FVC by pulmonary function testing.</description>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.09"/>
                    <measurement group_id="O2" value="-0.19" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Skeletal Muscle Strength</title>
        <description>Skeletal muscle strength will be assessed by pincher and grip dynamometry</description>
        <time_frame>6 months and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revatio (Sildenafil)</title>
            <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Skeletal Muscle Strength</title>
          <description>Skeletal muscle strength will be assessed by pincher and grip dynamometry</description>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pinch strength</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.30"/>
                    <measurement group_id="O2" value="0.12" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grip strength</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.90"/>
                    <measurement group_id="O2" value="0.17" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ejection Fraction</title>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Revatio (Sildenafil)</title>
          <description>This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
Sildenafil: 20mg tablet three times daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death from heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>fecal impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>low blood pressure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>tingling sensation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathryn Wagner, MD, PhD</name_or_title>
      <organization>Kennedy Krieger Institute</organization>
      <phone>443-923-9525</phone>
      <email>wagnerk@kennedykrieger.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

